

Shankar Vallabhajosula

Molecular Imaging and Targeted Therapy

Radiopharmaceuticals and Clinical
Applications

Second Edition

Editorial Assistance

By

Brigitte Vallabhajosula, Ph.D.

 Springer

Contents

1	Molecular Imaging and Targeted Radionuclide	
	Therapy: Introduction	1
1.1	Nuclear Medicine	1
1.2	Molecular Medicine	2
1.3	Molecular Imaging	3
1.3.1	Definitions	4
1.3.2	Molecular Imaging Technologies	5
1.4	Radiation Therapy	12
1.4.1	Targeted Radionuclide Therapy (TRT)	13
1.4.2	Personalized Medicine and Theranostics	14
1.5	Summary	18
	References	18
2	Science of Atomism: A Brief History	21
2.1	Atomism	21
2.2	Chemical Elements	22
2.2.1	Chemical Laws	22
2.2.2	Atomic Theory	23
2.3	Electricity and Magnetism	23
2.3.1	Electrolysis	24
2.3.2	Electromagnetism	25
2.4	Thermodynamics	26
2.4.1	Heat, Energy, and Temperature	26
2.4.2	Emission of Light	27
2.5	Major Discoveries	27
2.5.1	Cathode Rays	27
2.5.2	X-Rays	28
2.5.3	Electron	28
2.5.4	Radioactivity	29
2.5.5	Light Quantum	30
2.6	Reality of Atoms	31
2.6.1	Avogadro's Number	31
2.6.2	Brownian Motion	31
2.7	Atomic Structure	32
2.7.1	Nuclear Atom	32
2.7.2	Bohr's Model of Atom	32
2.7.3	Isotopes	33

2.7.4	Quantum Atom	33
2.7.5	Discovery of Antimatter	34
2.8	The Elementary Particles	34
	Further Reading	35
3	Atoms and Radiation	37
3.1	Matter and Energy	37
3.1.1	Mass–Energy Relationship	37
3.2	Radiation	38
3.2.1	Electromagnetic Radiation	38
3.3	Classification of Matter	39
3.3.1	Chemical Element	40
3.4	Atoms	40
3.4.1	Atomic Structure	41
3.4.2	The Bohr Model of an Atom	41
3.5	Nuclear Structure	43
3.5.1	Composition and Nuclear Families	43
3.5.2	Nuclear Binding Energy	43
3.5.3	Nuclear Stability	44
3.6	Atomic and Nuclear Emissions	45
3.6.1	Emissions from Electron Shells	45
3.6.2	Nuclear Emissions	46
	Further Reading	47
4	Radioactivity	49
4.1	The Discovery	49
4.2	Nuclear Disintegration	50
4.2.1	Types of Radioactive Decay	52
4.2.2	Radioactive Decay Series	56
4.2.3	Nuclear Fission	58
4.3	Radioactive Decay Equations	58
4.3.1	Exponential Decay	58
4.3.2	Units of Activity	59
4.3.3	Half-Life and Average Lifetime	59
4.3.4	Specific Activity	60
4.3.5	Serial Radioactive Decay	61
	Further Reading	62
5	Radioactivity Detection: PET and SPECT Scanners	63
5.1	Interaction of Radiation with Matter	63
5.1.1	Interactions of Charged Articles	63
5.1.2	Interaction of High-Energy Photons	64
5.1.3	Attenuation	66
5.2	Radiation Detectors	67
5.2.1	Ionization Detectors	67
5.2.2	Scintillation Detectors	68
5.3	Radionuclide Imaging Systems	71
5.3.1	SPECT/CT Scanner	72
5.3.2	PET Scanners	75
5.3.3	Small-Animal Imaging Systems	82
	References	85

6	Chemistry: Basic Principles	87
6.1	Chemical Elements	87
6.1.1	Chemistry and Radioactivity	87
6.1.2	Periodic Table	88
6.1.3	Chemical Bonding	91
6.2	Chemical Reactions	95
6.2.1	Types of Chemical Reactions	95
6.2.2	Chemical Equilibrium	97
6.3	Organic Chemistry	100
6.3.1	Hydrocarbons	101
6.4	Biochemistry	106
6.4.1	Proteins	106
6.4.2	Carbohydrates	108
6.4.3	Lipids	109
6.4.4	Nucleic Acids	112
	Further Reading	116
7	Cell and Molecular Biology	117
7.1	Introduction	117
7.2	Cell Structure and Function	117
7.2.1	The Plasma Membrane	118
7.2.2	Cytoplasm and Its Organelles	120
7.2.3	Cytoskeleton	121
7.2.4	Nucleus	122
7.3	Cell Reproduction	122
7.3.1	The Cell Cycle	122
7.3.2	Rates of Cell Division	123
7.4	Cell Transformation and Differentiation	124
7.5	Normal Growth	125
7.5.1	Cell Types	125
7.5.2	Tissue Types	125
7.6	Cell-to-Cell Communication	126
7.6.1	Cell–Cell Interaction	126
7.6.2	Cell Signaling and Cellular Receptors	127
7.7	Transport Through the Cell Membrane	128
7.7.1	Diffusion	130
7.7.2	Active Transport	131
7.7.3	Transport by Vesicle Formation	132
7.7.4	Transmission of Electrical Impulses	132
7.8	Cellular Metabolism	133
7.8.1	Role of ATP	133
7.9	DNA and Gene Expression	135
7.9.1	DNA: The Genetic Material	135
7.9.2	Gene Expression and Protein Synthesis	138
7.10	Disease and Pathophysiology	141
7.10.1	Homeostasis	141
7.10.2	Disease Definition	142
7.10.3	Pathophysiology	142
	Further Reading	145

8	Production of Radionuclides	147
8.1	Natural Radioactivity	147
8.1.1	Decay Chain	147
8.2	Nuclear Transformation	148
8.2.1	Artificial Production of Radioactivity	149
8.2.2	Nuclear Fission	150
8.2.3	Nuclear Reactions	151
8.3	Production of Radionuclides by Accelerators	153
8.3.1	Linear Particle Accelerator (LINAC)	154
8.3.2	Cyclotron	156
8.3.3	PET Radionuclides	158
8.3.4	SPECT Radionuclides	165
8.3.5	Therapy Radionuclides	166
8.4	Production of Radionuclides in a Nuclear Reactor	168
8.4.1	Nuclear Fission	168
8.4.2	Radionuclides Produced by Fission	169
8.4.3	Radionuclides Produced by Neutron Activation	170
8.4.4	Beta Emitting Radionuclides for Therapy	171
8.4.5	Alpha Emitting Radionuclides for Therapy	176
8.5	Radionuclide Generators	176
8.5.1	Generators for SPECT/PET Imaging	178
8.5.2	Generators for Radionuclide Therapy	179
	References	181
9	Radiopharmaceuticals for Molecular Imaging	185
9.1	Radiotracer Vs. Radiopharmaceutical	185
9.1.1	Radiopharmaceutical Vs. Radiochemical	185
9.2	Radiopharmaceuticals for Molecular Imaging (RP-MI)	186
9.2.1	Molecular Medicine and Theranostics	188
9.2.2	RPMI: Categories and Types	191
9.2.3	Choice of Radionuclide for SPECT and PET	192
9.2.4	General Criteria for the Design of RP-MI	194
9.2.5	General Methods of Radiolabeling	206
9.2.6	Automated Synthesis Modules	208
	References	209
10	Radiohalogens for Molecular Imaging (Fluorine and Iodine)	213
10.1	Fluorine-18 Radiopharmaceuticals for Molecular Imaging	213
10.1.1	Halogens	214
10.2	Chemistry of ^{18}F -Labeled Radiopharmaceuticals	215
10.2.1	Production of Fluorine-18	215
10.2.2	F-18 Radiochemistry	217
10.2.3	Fluorination Reactions	218
10.2.4	Radiotracers Based on Nucleophilic Reactions	221
10.2.5	Radiotracers Based on Electrophilic Reaction	229
10.2.6	F-18 Labeling of Peptides and Biomolecules	230
10.3	Radioiodinated Radiopharmaceuticals	233
10.3.1	Production of ^{123}I and ^{124}I	233
10.3.2	Chemistry of Iodine and Radioiodination	234
10.3.3	$^{123/131}\text{I}$ -Labeled Radiopharmaceuticals	236
	References	238

11 Organic Radionuclides for Molecular Imaging (C, N, and O)	243
11.1 Advantages of Organic Radionuclides	243
11.2 ^{11}C -Labeled Radiopharmaceuticals	244
11.2.1 Production of ^{11}C	244
11.2.2 ^{11}C Precursors	245
11.2.3 Synthesis of ^{11}C Labeled MIPs	248
11.3 ^{13}N -Labeled Radiopharmaceuticals	254
11.3.1 ^{13}N Ammonia (NH_3)	254
11.3.2 Synthesis of ^{13}N Gemcitabine	255
11.4 ^{15}O -Labeled Radiotracers	255
11.4.1 ^{15}O -Labeled Gases	255
11.4.2 Synthesis of ^{15}O Water	256
References	256
12 Metal Radionuclides for Molecular Imaging	259
12.1 Introduction	259
12.2 Radiometals for PET and SPECT	260
12.2.1 Specific Activity of Radiometals	261
12.2.2 Decay Characteristics of Radiometals	261
12.3 Chemistry of Radiometals	263
12.3.1 Chelators for Metal Complexation	263
12.3.2 Chemistry of Post-transition Metals	270
12.3.3 Chemistry of Transition Metals	275
12.4 Immuno-PET and SPECT	279
12.4.1 ImmunoPET: Applications	280
12.5 Technetium-99m Chemistry	283
12.5.1 Tc-Tricarbonyl Core, $[\text{Tc}(\text{CO})_3]^+$	285
References	286
13 Pharmacokinetics and Modeling	291
13.1 Quantitation	291
13.1.1 Standardized Uptake Value	291
13.2 Physiological Modeling	292
13.2.1 Radiotracer Binding	293
13.2.2 Tracer Kinetics	295
References	301
14 Molecular Imaging in Oncology	303
14.1 Cancer and Molecular Imaging	303
14.1.1 Radiopharmaceuticals for Molecular Imaging	304
14.2 Tumor Pathology and Biology	305
14.2.1 Histopathology	305
14.3 Molecular Basis of Cancer	306
14.3.1 Hallmarks of Cancer	306
14.3.2 Genetic Changes	307
14.3.3 Tumor Angiogenesis	309
14.3.4 Tumor Microenvironment	310
14.4 PET and SPECT Radiopharmaceuticals in Oncology	310
14.4.1 Objectives	310

14.4.2	Radiopharmaceuticals: Biochemical Basis of Localization	311 354
14.4.3	Antigen-Antibody Binding	364
	References	375
15	Molecular Imaging in Neurology	375
15.1	Neuroscience	375
15.1.1	The Nervous System	375
15.1.2	Nerve Cells	377
15.1.3	The Human Brain	379
15.1.4	Neural Signaling	379
15.1.5	Synaptic Transmission	380
15.1.6	Neurotransmitters and Receptors	382
15.2	Neurodegenerative Diseases	383
15.2.1	Dementia	386
15.2.2	Parkinson's Disease	386
15.3	Radiopharmaceuticals for Brain Imaging in Neurology	386 387
15.3.1	Cerebral Blood Flow and Perfusion	390
15.3.2	Cerebral Oxygen Metabolism	392
15.3.3	Cerebral Glucose Metabolism	394
15.3.4	β -Amyloid Neuritic Plaque Density	400
15.3.5	Tau Imaging in Dementia	402
15.3.6	Dopaminergic System	409
15.3.7	Neuroinflammation	413
15.4	Epilepsy	414
15.4.1	Blood Flow and Metabolism	415
15.5	Neurooncology	415
15.5.1	Imaging in Neuro-oncology	416
15.5.2	PET Radiotracers in Neuro-oncology	418
	References	418
16	Molecular Imaging in Cardiology	425
16.1	Nuclear Cardiology	425
16.2	The Clinical Problem	426
16.2.1	Coronary Artery Disease	426
16.2.2	Congestive Heart Failure	429
16.2.3	Cardiomyopathy	430
16.2.4	Fibrosis	431
16.3	Radiopharmaceuticals in Nuclear Cardiology	431
16.3.1	Myocardial Blood Flow/Perfusion	431
16.3.2	Myocardial Metabolism	436
16.3.3	Myocardial Presynaptic Adrenergic Neuronal Imaging	442
16.3.4	Cardiac Sarcoidosis (CS)	446
16.3.5	Cardiac Amyloidosis (CA)	448
16.3.6	Cardiac Fibrosis	451
16.3.7	Inflammation and Atherosclerosis	453
	References	456

17 Radiopharmaceuticals for Therapy	461
17.1 Introduction	461
17.2 Radiopharmaceuticals	462
17.2.1 Therapy Radiopharmaceuticals	462
17.3 Radionuclides for Therapy	464
17.3.1 Radionuclides-Emitting Beta Particles	464
17.3.2 Radionuclides-Emitting Alpha Particles	470
17.3.3 Radionuclides Emitting Low-Energy Electrons	474
17.3.4 In Vivo Radionuclide Generators	475
17.3.5 Mechanism and Biological Effects	475
17.3.6 Biological Effectiveness of Radionuclide Therapy	478
17.4 Design of Radiopharmaceuticals for TRT	479
17.4.1 Ideal Characteristics	479
17.4.2 Selection of Therapeutic Radionuclide	480
17.4.3 Theranostic Pair of Radionuclides	481
17.4.4 Biological Target and Targeting Vehicle	481
17.4.5 Radiolabeling Methods	483
17.5 Therapy Radiopharmaceuticals Approved for Clinical Use	484
17.5.1 Inorganic Ions	485
17.5.2 Inorganic Chelate Complex	487
17.5.3 Particulate Carriers	488
17.5.4 Small Organic Molecules	489
17.5.5 Regulatory Peptides Hormone Analogs	490
17.5.6 Monoclonal Antibodies	492
17.6 Prostate Specific Membrane Antigen (PSMA)	495
17.6.1 PSMA Inhibitors	495
References	496
18 Chemistry of Therapeutic Radionuclides	501
18.1 Targeted Radionuclide Therapy	501
18.1.1 Radionuclides for Therapy	501
18.1.2 Production of Radionuclides	502
18.2 Chemical Groups Radionuclides	506
18.3 Chemistry of Halogens	508
18.3.1 Iodine and Radioiodination	509
18.3.2 Chemistry of Astatine	512
18.4 Chemistry of Radiometals	515
18.4.1 Chelators for Metal Complexation	515
18.4.2 Bifunctional Chelating Agents	521
18.4.3 Alkaline Earth Metals	523
18.4.4 Transition Metals	524
18.4.5 Post-Transition Metals	526
18.4.6 Lanthanides	527
18.4.7 Actinides	528
References	529

19	Radiolabeled Antibodies for Imaging and Targeted Therapy...	533
19.1	Introduction	533
19.2	Antibody Structure and Function	536
19.2.1	Pharmacokinetics of Antibodies and Fragments	538
19.3	Hallmarks of Cancer	539
19.4	Cancer and Immunotherapy	540
19.4.1	Mechanisms of Action of mAbs	540
19.5	Radiolabeled Antibodies	541
19.5.1	FDA-Approved Radiolabeled Antibodies for Imaging and Therapy	542
19.5.2	Tumor Antigen Targets and Targeting Vehicles	543
19.5.3	Radionuclides for Antibody Therapy and Imaging ..	544
19.5.4	Radiolabeling and Bioconjugation Strategies of Antibodies	548
19.6	Radioimmunotherapy (RIT)	551
19.6.1	Direct and Indirect RIT Strategies	552
19.7	RIT: Clinical Applications	552
19.7.1	Hematological Malignancies	552
19.7.2	Solid Tumors	558
19.8	Strategies to Increase the Therapeutic Efficacy of RIT	561
19.8.1	Dose Fractionation	561
19.8.2	Pretargeted RIT (PRIT)	562
19.8.3	Combination RIT	563
19.9	Immuno-PET and SPECT of Cancer	564
19.9.1	⁸⁹ Zr for ImmunoPET	564
19.9.2	¹²⁴ I for ImmunoPET	565
19.9.3	ImmunoPET: Applications	566
19.9.4	Molecular Imaging for Cancer Immunotherapy	569
	References	571
20	Design of Radiolabeled Peptide Radiopharmaceuticals	577
20.1	Introduction	577
20.1.1	Proteinogenic and Non-proteinogenic AAs	577
20.1.2	Peptide Therapeutics	580
20.1.3	Advantages and Disadvantages of Peptides	581
20.2	Design of Peptide Radiopharmaceuticals (PRP)	582
20.2.1	Peptide Modification and Insertion of Non-natural AAs ..	583
20.2.2	Peptide Cyclization	584
20.2.3	Insertion of β -Amino Acids	586
20.2.4	Substitution of Amides with Sulfonamides	587
20.2.5	N-Methylation (N-Alkylation)	587
20.2.6	PEGylation	588
20.2.7	Glycosylation	588
20.2.8	Albumin Binding	590
20.2.9	Spacers/Linkers	591
20.2.10	Dimerization and Multimerization	591

20.3	Radiolabeling of Peptides	593
20.3.1	Radionuclides.....	593
20.3.2	Radiolabeling Methods	594
20.3.3	Peptide Labeling with Radioiodine	594
20.3.4	Peptide Labeling with Fluorine-18	595
20.3.5	Peptide Labeling with Trivalent Radiometals	596
20.3.6	Peptide Labeling with ^{99m} Tc.....	602
	References.....	605
21	Theranostics in Neuroendocrine Tumors	609
21.1	Introduction	609
21.1.1	Carcinoid Syndrome	610
21.1.2	Therapeutic Modalities	611
21.2	Theranostics in NETs.....	612
21.2.1	Biological Targets	614
21.2.2	Radionuclides for Imaging and Therapy	614
21.2.3	Radiolabeling Methods	617
21.3	Somatostatin Receptors and SST Analogs.....	617
21.3.1	Imaging SSTR-Positive NETs Radiolabeled SST Agonist Analogs for Imaging.....	620
21.3.2	Therapy of SSTR-2-Positive NETs	627
21.3.3	Therapy with Alpha Particles.....	632
21.4	Norepinephrine Transporter (NET): Imaging and Therapy Agents	633
21.4.1	MIBG Analogs for Imaging.....	633
21.4.2	Therapy with MIBG (Azedra®)	635
21.5	Glucose Transporters (GLUT).....	637
21.6	Amino Acid Transporters (AATs)	638
21.6.1	[¹¹ C]-5-HTP	639
21.6.2	[¹⁸ F]FDOPA	639
21.7	Glucagon-Like Peptide 1 Receptor (GLP-IR)	640
21.8	Cholecystokinin-2 Receptor (CCK2R)	642
21.9	Neurotensin Receptor 1 (NTR1)	642
21.10	Chemokine Receptor-4 (CXCR-4).....	644
21.11	Tumor Antigens and RIT	646
21.12	Embolization Therapy with ⁹⁰ Y-Microspheres.....	647
	References.....	648
22	Theranostics in Prostate Cancer	655
22.1	Prostate Cancer	655
22.1.1	Screening and Diagnosis	655
22.1.2	Treatment for Localized Prostate Cancer.....	656
22.1.3	Role of Imaging in Prostate Cancer.....	657
22.2	Biological Targets in mCRPC	658
22.2.1	Bone Matrix	658
22.2.2	Androgen Receptor (AR).....	660
22.2.3	Prostate-Specific Membrane Antigen (PSMA)	662
22.2.4	Gastrin Releasing Peptide Receptor (GRPR)	665

22.3	Radionuclides for Imaging and Therapy	666
22.3.1	Beta vs. Alpha Dosimetry	666
22.3.2	Radiolabeling Methods	668
22.4	Radiopharmaceuticals for SPECT and PET	669
22.4.1	Bone Matrix	670
22.4.2	Glucose Metabolism	670
22.4.3	Lipid Metabolism	672
22.4.4	Amino Acid (AA) Transport	673
22.4.5	Androgen Receptor	674
22.4.6	Radiolabeled Antibodies	676
22.4.7	Small-Molecule PSMA Inhibitors	678
22.4.8	Bombesin and GRPR Analogs	687
22.5	Radiopharmaceuticals for Bone Pain Palliation	688
22.5.1	^{89}Sr Dichloride (Metastron [®])	688
22.5.2	Bisphosphonates: ^{153}Sm -EDTMP (Quadramet [®])	689
22.6	Radiopharmaceuticals for Targeted Therapy	690
22.6.1	^{223}Ra Dichloride (Xofigo)	690
22.6.2	RIT with ^{177}Lu - or ^{225}Ac -Labeled J591 mAb	691
22.6.3	Small-Molecule PSMA Inhibitors	693
22.7	Combination Therapy	696
	References	697
	Index	705